Fig 1.
Flow diagram.
Fig 2.
Example of the Andersen-Gill design.
Table 1.
Baseline data of patients included in the cohort[1].
Table 2.
Association between mode of proton inhibition pump use and incident chronic kidney disease.
Table 3.
Risk of incident chronic kidney disease with proton inhibition pumps use.
Multivariate analysis in a cohort before correcting left censoring (only participants with available measurements of eGFR and/or UACR).
Table 4.
Variables related to incident chronic renal disease in participants that used proton inhibition pump compared with nonusers.
Multivariate analysis. Table 4 shows the variables related to incident CKD in participants that used PPIs compared with nonusers.
Fig 3.
Chronic kidney disease survival rate in proton inhibition pump never exposed and exposed subjects (Andersen-Gill survival model).
p-values of the log-rank tests: PPI never user vs. PPI at baseline p<0.001; PPI at baseline vs. PPI only during follow-up p<0.001; PPI never user vs. PPI at baseline and/or during follow-up p<0.001.